title: Differential regulation of nitric oxide production by increase of intracellular cAMP in murine primary fibroblasts and L929 fibrosarcoma cell line.
abstract: The effect of intracellular cAMP rise on nitric oxide (NO) production was compared in murine primary fibroblasts isolated from the spleens of CBA mice, and L929 fibrosarcoma cell line. Treatment of confluent L929 cells with cAMP analogues -dibutyryl-cAMP (db-cAMP) or 8-Cl-cAMP caused dose-dependent augmentation of inducible NO synthase (iNOS)-mediated NO production, which has been abrogated by inhibition of protein synthesis with cycloheximide or addition of selective iNOS inhibitor aminoguanidine. In contrast, under the same cultivating conditions, cAMP analogues were not able to upregulate NO synthesis in primary fibroblasts. Treatment with cAMP analogues or non-selective phosphodiesterase (PDE) inhibitor pentoxifylline affected IFNgamma-induced NO synthesis in both cell types, but in the opposite manner-enhancing in L929 cells and suppressive in primary fibroblasts. The induction of iNOS, but not its catalytic activity, was impaired in cAMP-treated primary fibroblasts. Finally, PDE type IV inhibitor rolipram enhanced IFN-gamma-triggered NO synthesis in L929 cells, but was unable to mimic cAMP analogue or PTX-mediated suppression of NO synthesis in spleen fibroblasts. These results suggest that, in contrast to L929 fibrosarcoma cell line, intracellular cAMP rise might have a role in downregulation of NO production in murine primary fibroblasts.
authors.affiliation: Institute for Biological Research, 'Sinisa Stankovic', 29. Novembra 142, 11000, Belgrade, Yugoslavia. imuno@eunet.yu
authors.forename: T
authors.initials: T
authors.lastname: Samardzic
authors.forename: S
authors.initials: S
authors.lastname: Stosic-Grujicic
authors.forename: D
authors.initials: D
authors.lastname: Maksimovic
authors.forename: V
authors.initials: V
authors.lastname: Jankovic
authors.forename: V
authors.initials: V
authors.lastname: Trajkovic
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002384:Catalysis; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism*; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism; D005354:Fibrosarcoma; D007371:Interferon-gamma / Q000494:pharmacology; D007424:Intracellular Fluid / Q000378:metabolism; D051379:Mice; D008808:Mice, Inbred CBA; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D020889:Rolipram / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D010726:Phosphodiesterase Inhibitors; D015124:8-Bromo Cyclic Adenosine Monophosphate; D009569:Nitric Oxide; D003994:Bucladesine; D007371:Interferon-gamma; C044258:8-chloro-cyclic adenosine monophosphate; D000242:Cyclic AMP; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D020889:Rolipram; D015056:1-Methyl-3-isobutylxanthine